Compare Crispr Therapeutics AG (CRSP) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Schlumberger NV — how do they compare? Crispr Therapeutics AG trades at $53.88 (market cap $5.17B), while Schlumberger NV trades at $53.7 (market cap $78.96B). The key difference: Schlumberger NV is far larger — about 15.3× Crispr Therapeutics AG's market cap, and Schlumberger NV pays a 2.22% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | SLB | |
|---|---|---|
Market Cap | $5.17B | $78.96B |
Sector | Health | Energy |
52-Week High | $76.78 | $58.01 |
52-Week Low | $44.34 | $31.72 |
Enterprise Value | $3.59B | $87.68B |
Dividend Yield | — | 2.22% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
